BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Entry into a Material Definitive Agreement

BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

Story continues below

Effective August 18, 2017, Bone Biologics Corporation (the “Company”) entered into an Amended and Restated Exclusive License Agreement (the “Restated License Agreement”) with The Regents of the University of California (the “Regents”). The Restated License Agreement, amends and restates the Exclusive License Agreement, effective March 15, 2006, between the Company and the Regents, as amended by ten amendments. Under the Restated License Agreement, the Company continues to be responsible for the development and commercialization for Nell-1 (the “Licensed Product”). The Licensed Product is a recombinant human protein growth factor that is essential for normal bone development. Under the terms of the Restated License Agreement, the Regents have continued to grant the Company exclusive rights to develop and commercialize the Licensed Product for use in spinal fusions which was the initial field of use for the Licensed Product and have added osteoporosis and trauma as additional fields of use.

The foregoing description of the Restated License Agreement does not purport to be complete, and is qualified in its entirety by reference to the full text of the Restated License Agreement, which is filed as an exhibit to this report and incorporated herein by reference.

On August 23, 2017, the Company issued a press release regarding the Restated License Agreement.

Item 9.01. Financial Statements and Exhibits.

There is filed as part of this report the exhibit listed on the accompanying Index to Exhibits, which information is incorporated herein by reference.

Exhibit No. Description
10.1 Amended and Restated Exclusive License Agreement, dated as of August 18, 2017, by and between the Company and The Regents of the University of California
99.1 Press Release dated August 23, 2017 relating to the Amended and Restated Exclusive License Amendment

Index to Exhibits

Exhibit No. Description
10.1 Amended and Restated Exclusive License Agreement, dated as of August 18, 2017, by and between the Company and The Regents of the University of California
99.1 Press Release dated August 23, 2017 relating to the Amended and Restated License Amendment


Bone Biologics Corp Exhibit
EX-10.1 2 ex10-1.htm   EXHIBIT 10.1   AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT   THIS AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made as of June 19,…
To view the full exhibit click here

About BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG)

Bone Biologics Corporation is a biotechnology company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. The Company’s platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. The Company’s platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The NELL-1/DBX Fusion Device will consist of a single dose vial of NELL-1 recombinant protein freeze dried onto DBX.

An ad to help with our costs